BACKGROUND AND AIMS:Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related deaths. Patients with advanced HCC are treated with sorafenib. A recent randomized controlled trial demonstrated a survival benefit for regorafenib treatment in patients with advanced HCC who had progressed on sorafenib. We aimed to evaluate the cost-effectiveness of this approach. METHODS:To evaluate the cost effectiveness of regorafenib, we used a Markov model that incorporates health outcomes, measured by life-years and quality-adjusted life-years (QALYs). Drug costs were based on 2017 discounted prices. Model robustness was validated by probabilistic sensitivity analyses using Monte Carlo simulations. RESULTS:The use of regorafenib results ...
<p><b>A-F</b>. Estimates of incremental net benefit (i.e. incremental cost-effectiveness ratio, ICER...
Introduction: Sorafenib is the standard of care for patients with advanced hepatocellular carcinoma ...
Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatoc...
Background and aimsHepatocellular carcinoma (HCC) is one of the leading causes of cancer related dea...
The purpose was to assess the cost-effectiveness of sorafenib in the treatment of hepatocellular car...
The purpose was to assess the cost-effectiveness of sorafenib in the treatment of hepatocellular car...
Hepatocellular carcinoma (HCC) is a worldwide problem, with a high prevalence in nonindustrialized c...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/138237/1/cncr30863.pdfhttps://deepblue...
Abstract Objectives Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globa...
Hepatocellular carcinoma (HCC) presentation is heterogeneous necessitating a variety of therapeutic ...
Abstract Background Sorafenib and transarterial chemoembolization (TACE) might both provide survival...
Background/Aims Regorafenib has been approved as a second-line systemic therapy for hepatocellular c...
Objectives: To perform a cost-effectiveness analysis comparing the use of transarterial radioemboliz...
BackgroundIn the CELESTIAL trial for patients with advanced hepatocellular carcinoma (HCC), cabozant...
none24siPublished Online December 5, 2016Background: There are no systemic treatments for patients w...
<p><b>A-F</b>. Estimates of incremental net benefit (i.e. incremental cost-effectiveness ratio, ICER...
Introduction: Sorafenib is the standard of care for patients with advanced hepatocellular carcinoma ...
Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatoc...
Background and aimsHepatocellular carcinoma (HCC) is one of the leading causes of cancer related dea...
The purpose was to assess the cost-effectiveness of sorafenib in the treatment of hepatocellular car...
The purpose was to assess the cost-effectiveness of sorafenib in the treatment of hepatocellular car...
Hepatocellular carcinoma (HCC) is a worldwide problem, with a high prevalence in nonindustrialized c...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/138237/1/cncr30863.pdfhttps://deepblue...
Abstract Objectives Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globa...
Hepatocellular carcinoma (HCC) presentation is heterogeneous necessitating a variety of therapeutic ...
Abstract Background Sorafenib and transarterial chemoembolization (TACE) might both provide survival...
Background/Aims Regorafenib has been approved as a second-line systemic therapy for hepatocellular c...
Objectives: To perform a cost-effectiveness analysis comparing the use of transarterial radioemboliz...
BackgroundIn the CELESTIAL trial for patients with advanced hepatocellular carcinoma (HCC), cabozant...
none24siPublished Online December 5, 2016Background: There are no systemic treatments for patients w...
<p><b>A-F</b>. Estimates of incremental net benefit (i.e. incremental cost-effectiveness ratio, ICER...
Introduction: Sorafenib is the standard of care for patients with advanced hepatocellular carcinoma ...
Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatoc...